Literature DB >> 9694901

A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.

Y Hou1, B McInnes, A Hinek, G Karpati, D Mahuran.   

Abstract

The GM2 gangliosidoses are caused by mutations in the genes encoding the alpha- (Tay-Sachs) or beta- (Sandhoff) subunits of heterodimeric beta-hexosaminidase A (Hex A), or the GM2 activator protein (AB variant), a substrate-specific co-factor for Hex A. Although the active site associated with the hydrolysis of GM2 ganglioside, as well as part of the binding site for the ganglioside-activator complex, is associated with the alpha-subunit, elements of the beta-subunit are also involved. Missense mutations in these genes normally result in the mutant protein being retained in the endoplasmic reticulum and degraded. The mutations associated with the B1-variant of Tay-Sachs are rare exceptions that directly affect residues in the alpha-active site. We have previously reported two sisters with chronic Sandhoff disease who were heterozygous for the common HEXB deletion allele. Cells from these patients had higher than expected levels of mature beta-protein and residual Hex A activity, approximately 20%. We now identify these patients' second mutant allele as a C1510T transition encoding a beta-Pro504 --> Ser substitution. Biochemical characterization of Hex A from both patient cells and cotransfected CHO cells demonstrated that this substitution (a) decreases the level of heterodimer transport out of the endoplasmic reticulum by approximately 45%, (b) lowers its heat stability, (c) does not affect its Km for neutral or charged artificial substrates, and (d) lowers the ratio of units of ganglioside/units of artificial substrate hydrolyzed by a factor of 3. We concluded that the beta-Pro504 --> Ser mutation directly affects the ability of Hex A to hydrolyze its natural substrate but not its artificial substrates. The effect of the mutation on ganglioside hydrolysis, combined with its effect on intracellular transport, produces chronic Sandhoff disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694901     DOI: 10.1074/jbc.273.33.21386

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Role of beta Arg211 in the active site of human beta-hexosaminidase B.

Authors:  Y Hou; D Vocadlo; S Withers; D Mahuran
Journal:  Biochemistry       Date:  2000-05-23       Impact factor: 3.162

2.  An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants).

Authors:  Joe T R Clarke; Don J Mahuran; Swati Sathe; Edwin H Kolodny; Brigitte A Rigat; Julian A Raiman; Michael B Tropak
Journal:  Mol Genet Metab       Date:  2010-09-17       Impact factor: 4.797

3.  Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis.

Authors:  S Zhang; R Bagshaw; W Hilson; Y Oho; A Hinek; J T Clarke; J W Callahan
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

4.  Characterization of the Glu and Asp residues in the active site of human beta-hexosaminidase B.

Authors:  Y Hou; D J Vocadlo; A Leung; S G Withers; D Mahuran
Journal:  Biochemistry       Date:  2001-02-20       Impact factor: 3.162

5.  Characterization of the mutant β-subunit of β-hexosaminidase for dimer formation responsible for the adult form of Sandhoff disease with the motor neuron disease phenotype.

Authors:  Kenichiro Yamada; Yuhei Takado; Yusuke S Kato; Yasukazu Yamada; Hideaki Ishiguro; Nobuaki Wakamatsu
Journal:  J Biochem       Date:  2012-11-05       Impact factor: 3.387

6.  Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.

Authors:  Brian L Mark; Don J Mahuran; Maia M Cherney; Dalian Zhao; Spencer Knapp; Michael N G James
Journal:  J Mol Biol       Date:  2003-04-11       Impact factor: 5.469

7.  Identification of the 6-sulfate binding site unique to alpha-subunit-containing isozymes of human beta-hexosaminidase.

Authors:  R Sharma; H Deng; A Leung; D Mahuran
Journal:  Biochemistry       Date:  2001-05-08       Impact factor: 3.162

8.  Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients.

Authors:  Michael B Tropak; Stephen P Reid; Marianne Guiral; Stephen G Withers; Don Mahuran
Journal:  J Biol Chem       Date:  2004-01-14       Impact factor: 5.157

9.  Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.

Authors:  Michael B Tropak; Gregory J Kornhaber; Brigitte A Rigat; Gustavo H Maegawa; Justin D Buttner; Jan E Blanchard; Cecilia Murphy; Steven J Tuske; Stephen J Coales; Yoshitomo Hamuro; Eric D Brown; Don J Mahuran
Journal:  Chembiochem       Date:  2008-11-03       Impact factor: 3.164

10.  A single site in human beta-hexosaminidase A binds both 6-sulfate-groups on hexosamines and the sialic acid moiety of GM2 ganglioside.

Authors:  Rohita Sharma; Scott Bukovac; John Callahan; Don Mahuran
Journal:  Biochim Biophys Acta       Date:  2003-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.